300026 Share Price Performance
CN¥3.69
-0.77 (-17.26%)
Price CN¥3.69
Share PriceCN¥3.69
Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Seems To Use Debt Quite Sensibly
Nov 22
Tianjin Chase Sun Pharmaceutical Co.,Ltd Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
300026 Community Narratives
There are no narratives available yet.
Tianjin Chase Sun Pharmaceutical Co.,Ltd Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.016
- Gross Margin
- 50.43%
- Net Profit Margin
- -0.86%
- Debt/Equity Ratio
- 6.1%
Tianjin Chase Sun Pharmaceutical Co.,Ltd Competitors
Snowflake Analysis
About 300026
- Founded
- 1996
- Employees
- 5297
- CEO
- WebsiteView website
Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research and development, production, and sale of various pharmaceutical products in China and internationally. The company offers Chinese medicine granules, finished pharmaceutical products, raw materials and excipients, medical devices, medical and healthcare services, and smart supply chain for pharmaceutical and medical devices. It also provides its products in the areas of immunity, cardiovascular and cerebrovascular diseases, respiratory system, and neurodegenerative diseases, as well as anti-tumor. Tianjin Chase Sun Pharmaceutical Co.,Ltd was founded in 1996 and is headquartered in Tianjin, China.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Chinese Market Performance
- 7 Days: 0.5%
- 3 Months: 17.0%
- 1 Year: 24.1%
- Year to Date: 26.2%
Over the last 7 days, the market has remained flat, with no particular sector making any big moves this week. Meanwhile, the market is actually up 24% over the past year. Earnings are forecast to grow by 27% annually. Market details ›